Single-cell Multiomics Powers Biomarker Insights into AML MRD

The Tapestri Single-cell Measurable Residual Disease (scMRD) Multiomics Assay for Acute Myeloid Leukemia (AML) is the only solution that simultaneously conducts the genotypic and immunophenotypic assessment of AML MRD across thousands of individual cells, providing clonal insight in tandem with immunophenotype from rare residual disease cells. These high-resolution, integrated molecular profiles bring unprecedented clarity to the complex biology of AML MRD, powering crucial biomarker insights.

TALK TO A SCIENTIST

What if you could follow the clonal evolution of AML to uncover biomarker insights?

The complexity of leukemia clonal architecture and the genotypic  and phenotypic drifts during treatment explain why more than half of patients in remission could relapse. Addressing these with single-cell multiomics enables you to go beyond a binary MRD readout to gain crucial biomarker insights.

Key Benefits

Reveal Clonal Architecture and the Order of Acquisition of Mutations

Enables complex phylogenetic reconstruction to help you uncover clonal architecture and determine the order of acquisition of mutations.

Distinguish True AML from Preleukemic or Precursor Clones with a Limit of Detection of 0.01%

Integrates genotypic and phenotypic readouts to enable the distinction of residual AML clones from precursor clones such as MDS or clonal hematopoiesis.
Detects rare clones with a limit of detection of 0.01% and plots their signature differences in heat maps.

Track Clonal Dynamics and Identify Therapy-Resistant Clones and Novel Biomarkers

Enables longitudinal analysis of clonal dynamics over time from diagnosis, MRD to relapse.
Provides insights about tumor evolution and its correlation with relapse, treatment response dynamics, selective pressure, and therapy-resistant clones.

See an example report

It is time to overcome the challenges of MRD in AML

The heterogeneity and dynamism of AML clonal architecture pose a challenge for MRD monitoring. Yet, MRD assessment is crucial for prognosis, as MRD positivity post-remission indicates a higher relapse risk. Conventional single-analyte methods like flow cytometry and PCR are unable to detect the immunophenotypic or genotypic changes arising during treatment. While error-corrected NGS offers highly sensitive detection of residual cells and simultaneous evaluation of many genes, it cannot differentiate true AML from precursor clones, leading to false-positive results. Even when combining these assays to achieve clinical utility, integrating data from different modalities remains challenging.

Tapestri scMRD technology vs conventional methods for MRD assessment

Capabilities

Flow Cytometry

Error-corrected NGS

scMRD AML Multiomics Assay

Identify mutations driving therapy response

Detect rare events with high sensitivity

Characterize immunophenotypic and genotypic drift through disease course

Distinguish true AML from benign precursors

Uncover clonal architecture (co-occurrence and zygosity of mutation)

Tapestri Single-cell MRD AML Multiomics Solution

Get everything you need to conduct single-cell multiomics analysis of AML MRD samples in your lab with this fully-supported, all-in-one package.

Tapestri Instrument
Tapestri Single-Cell MRD AML Multiomics Kit including:
- Tapestri Single-Cell DNA + Protein Core Kit
- Tapestri scMRD AML DNA Panel
- TotalSeq-D scMRD AML Antibody Cocktail
Tapestri Single-Cell MRD AML Software (via Portal Access or On-Premise Activation)

Assay Content

40-hotspot-gene panel for single-cell DNA sequencing curated based on relevant guidelines for AML MRD  testing such as the European LeukemiaNet (ELN).
17-plex antibody oligonucleotide conjugate (AOC) panel including AML MRD disease-specific biomarkers for  immunophenotypic characterization.

Tapestri scMRD AML DNA Panel

TotalSeq-D scMRD AML Antibody Cocktail

"Current tools for MRD assessment, like bulk NGS and flow cytometry, lack the clonal resolution and specificity to detect the treatment-resistant cancer cells still hiding in the shadows. Mission Bio’s unique approach to characterizing MRD could dramatically change how we stratify patients in clinical trials and create personalized care strategies in the future.”

P.J.M. (Peter) Valk, PhD, Principal Investigator at Erasmus MC
Independent Mission Bio Platform User